ScreenerHero

SPAGO Spago Nanomedical AB (publ)

STO · SE · Healthcare · Biotechnology · spagonanomedical.se
0.1075SEK-2.27%Mkt Cap: 8.21M $P/E: —

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI con…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap8.21M USD
Enterprise Value5.29M USD
Revenue (TTM)364.24K USD
Gross Profit-1.06M USD
Net Income (TTM)-2.54M USD
Revenue/Share0.0070 SEK
Last Price0.1075 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0004899474
Valuation
P/E (Trailing)—
P/E (Forward)-2.20
PEG—
EV/EBITDA-2.11
EV/Revenue14.53
P/S23.06
P/B2.75
EPS (TTM)-0.04
EPS (Forward)—
52W Range
0.08009% of range0.3700
52W High0.3700 SEK
52W Low0.0800 SEK
Profitability
Gross Margin-2527.23%
Oper. Margin-736.68%
EBITDA Margin0.00%
Profit Margin-6076.43%
ROE-86.37%
ROA-72.39%
Growth
Revenue Growth-18.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.71M USD
CapEx (TTM)21.90K USD
FCF Margin-411.25%
FCF Yield-18.25%
Net Debt-3.11M USD
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity—
Current Ratio7.25
Quick Ratio6.44
Book Value/Sh0.04 SEK
Cash/Share0.04 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.2650 SEK
Upside (mean)+146.5%
Target Range0.2650 SEK – 0.2650 SEK
# Analysts1
Ownership
Shares Out.798.38M
Float282.89M
Insiders70.07%
Institutions8.96%
Technical
SMA 500.1091 (-1.4%)
SMA 2000.1155 (-6.9%)
Beta1.30
S&P 52W Chg16.45%
Avg Vol (30d)251.15K
Avg Vol (10d)215.98K
Technical Indicators
RSI (14)54.5
MACD-0.0012
MACD Signal-0.0029
MACD Hist.+0.0017
BB Upper0.1111 SEK
BB Middle0.1008 SEK
BB Lower0.0904 SEK
BB Width20.54%
ATR (14)0.0079 SEK
Vol Ratio (20d)2.37x